Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.24
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $10.6M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$37M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.4%
↓Gross Margin
16.7%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.3%
FCF CAGR
—
FCF margin
-63.3%
FCF / Net income
2.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85.9M · net income $-22.0M · FCF $-54.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85.9M | $85.9M | $85.2M | $107.8M | $175.9M |
| Net Income | $-22.0M | $-22.0M | $4.9M | $18.6M | $29.2M |
| EBITDA | $-20.2M | $-20.2M | $-7.6M | $25.5M | $61.1M |
| EPS | -0.14 | -0.14 | 0.03 | 0.13 | 0.22 |
| Gross Margin | 16.7% | 16.7% | 19.8% | 27.1% | 52.1% |
| Operating Margin | -26.4% | -26.4% | -13.1% | 17.1% | 34.9% |
| Net Margin | -25.7% | -25.7% | 5.7% | 17.3% | 16.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.13 | 0.24 | 0.29 |
| Current Ratio | 3.60 | 3.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-54.4M | $-54.4M | $10.6M | $320.6M | $-56.2M |
| Returns | |||||
| ROE | -7.4% | -7.4% | 1.5% | 7.0% | 11.9% |
| Valuation | |||||
| P/E | — | — | 11.57 | 11.37 | 8.99 |
| EV/EBITDA | — | — | — | -1.96 | 5.53 |
| P/B | 0.12 | 0.12 | 0.18 | 0.83 | 1.18 |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | -20.9% | -38.7% | — |
| EPS Growth | -527.6% | -527.6% | -73.6% | -42.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.03 → -0.14
Residual
-27.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.